Anh Nguyen
Chairman chez MedXCell SA
Fortune : 20 M $ au 31/03/2024
Profil
Anh Nguyen founded MedinCell SA in 2003, where he worked as Chairman-Supervisory Board from 2014 to 2024.
Dr. Nguyen also founded Syntro Corp.
and Life Technologies Corp.
Dr. Nguyen also currently works at MedXCell SA, as Chairman.
Dr. Nguyen also formerly worked at Emosis SAS, as Chairman-Supervisory Board.
Dr. Nguyen received his doctorate degree from the University of California San Diego and Masters Business Admin degree from MIT Sloan School of Management.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
MEDINCELL SA
6,62% | 30/06/2023 | 1 923 043 ( 6,62% ) | 20 M $ | 31/03/2024 |
Postes actifs de Anh Nguyen
Sociétés | Poste | Début |
---|---|---|
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | Chairman | - |
Anciens postes connus de Anh Nguyen
Sociétés | Poste | Fin |
---|---|---|
MEDINCELL S.A. | Founder | 15/02/2024 |
Emosis SAS
Emosis SAS Miscellaneous Commercial ServicesCommercial Services Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France. | Chairman | - |
Syntro Corp. | Founder | - |
Life Technologies Corp.
Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Founder | - |
Formation de Anh Nguyen
University of California San Diego | Doctorate Degree |
MIT Sloan School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MEDINCELL S.A. | Health Technology |
Entreprise privées | 4 |
---|---|
Syntro Corp. | Health Technology |
Life Technologies Corp.
Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Commercial Services |
Emosis SAS
Emosis SAS Miscellaneous Commercial ServicesCommercial Services Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France. | Commercial Services |
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | Health Technology |